This review examined the differences between races in treatment outcomes for prostate cancer. The authors' conclusion seemed to be that worse treatment outcomes do not appear to explain differences in prostate-cancer mortality between black and white men. The reliability of this conclusion is unclear, given the incomplete reporting of review methods, language restrictions and the lack of a validity assessment.
Results of the review
Twenty-nine studies (n=24,968) were included: 3 randomised controlled trials (n=3,661) and 26 retrospective studies of unspecified design.
Studies controlled for different confounders. Just under half of the studies (46%) controlled for age of onset, stage and grade of disease. Most studies did not report controlling for socioeconomic status and family history.
Twenty-three studies (79%) found no relationship between race and treatment outcomes.
There was no difference in outcomes for 10 (77%) of 13 studies assessing PSA failure or for 8 (73%) of 11 studies assessing overall or disease-free or disease-specific survival. Six studies (21%) found that the outcomes were worse among black men. Studies reporting a difference were more likely to be published in 1996 or before, to be in patients with metastatic disease, and were less likely to use radiotherapy treatment than studies reporting no difference.
No study found that white men had worse outcomes than black men.
Authors' conclusions
The review indicates that patients who undergo the same treatment have similar outcomes, irrespective of race. The authors therefore stated that efforts to narrow the racial gap in prostate cancer mortality should focus on ensuring that all populations are informed about screening for early detection and all patients receive optimal treatment.
CRD commentary
The review addressed a clear question that was defined in terms of the participants, intervention and outcomes; no inclusion criteria were reported for study design. Three relevant databases were searched, but restricting the primary studies to trials published in English raises the possibility of language and publication bias; the authors acknowledged this potential for publication bias. Methods were used to minimise errors and bias in the extraction of data, but it was unclear whether similar steps were taken at the study selection stage. The validity of the studies was not assessed, so the reliability of data derived from the included studies could not be fully assessed. Given the differences among studies, a narrative synthesis was appropriate and potential sources of difference between the studies were discussed and examined. The reliability of the authors' conclusion is unclear, given the incomplete reporting of review methods, the exclusion of non-English language studies and the lack of a validity assessment.
Implications of the review for practice and research
Practice: The authors stated that to narrow the disparity in mortality from prostate cancer-related mortality between black and white men, all patients should receive optimal treatment and information about screening for the early detection of cancer.
Research: The authors stated that research should focus on interventions to reduce presentation at an advanced stage of the disease and interventions to reduce disease-related mortality in black men. The authors further stated that a clearer understanding of the effectiveness of different treatment options is required, and that future studies addressing racial differences in outcome should control for socioeconomic factors and/or family history. 
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